Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile
暂无分享,去创建一个
Mark I. McCarthy | Pauline M. Rudd | Igor Rudan | Jennifer E. Huffman | Harry Campbell | Torben Hansen | Ulf Gyllensten | Caroline Hayward | Lina Zgaga | Mark W. J. Strachan | Alan F. Wright | Dragan Primorac | Ozren Polasek | Gordan Lauc | Anna L. Gloyn | Barbara Adamczyk | Olga Gornik | Iwar Klimes | Pål R. Njølstad | Jayesh J. Kattla | Mislav Novokmet | Irma Redzic | Ivana Kolcic | Trine Nielsen | M. McCarthy | T. Nielsen | T. Hansen | O. Pedersen | S. Wild | N. Hastie | K. Owen | I. Rudan | A. Wright | A. Gloyn | P. Njølstad | A. Bennett | N. Hassanali | C. Hayward | I. Kolčić | O. Polašek | H. Campbell | James F. Wilson | D. Gašperíková | J. Stanik | U. Gyllensten | L. Zgaga | I. Klimeš | B. Adamczyk | Abdelkader Essafi | P. Rudd | J. Huffman | D. Primorac | R. Reynolds | T. Hansen | E. Tjora | G. Lauc | M. Strachan | O. Gornik | M. Pučić | Irma Redžić | M. Novokmet | Sarah H. Wild | Amanda J. Bennett | Neelam Hassanali | Rebecca M. Reynolds | G. Thanabalasingham | Nicholas D. Hastie | A. Mužinić | Erling Tjora | Daniela Gasperikova | Katharine R. Owen | Gaya Thanabalasingham | Ana Muzinic | Maja Pucic | Saima A. Mughal | Juraj Stanik | Oluf B. Pedersen | Abdelkader Essa | J. Kattla | S. Mughal | A. Essa | U. Gyllensten | James F. Wilson | M. McCarthy | A. Wright | Igor Rudan | Alan F. Wright | T. Hansen | Oluf Pedersen | Nick Hastie | Harry Campbell | Iwar Klimeš | M. McCarthy | Pauline M. Rudd | M. Strachan | Pål R. Njølstad | Sarah H Wild | Rebecca M. Reynolds
[1] A. Gonzalez-Perez,et al. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.
[2] M. McCarthy,et al. Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young , 2012, Diabetes Care.
[3] David J. Harvey,et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. , 2008, Analytical biochemistry.
[4] B. Shields,et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes , 2011, Diabetes Care.
[5] Y. Matsuzawa,et al. Three new mutations in the hepatocyte nuclear factor-1α gene in Japanese subjects with diabetes mellitus: clinical features and functional characterization , 1999, Diabetologia.
[6] P. Bingley,et al. Islet autoantibodies can discriminate maturity‐onset diabetes of the young (MODY) from Type 1 diabetes , 2011, Diabetic medicine : a journal of the British Diabetic Association.
[7] R. Dwek,et al. Changes of serum glycans during sepsis and acute pancreatitis. , 2007, Glycobiology.
[8] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[9] B. Shields,et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? , 2010, Diabetologia.
[10] G. Lauc,et al. Stability of N-glycan profiles in human plasma. , 2009, Glycobiology.
[11] D. Santini,et al. The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. , 2011, The international journal of biochemistry & cell biology.
[12] I. Rudan,et al. Variability, heritability and environmental determinants of human plasma N-glycome. , 2009, Journal of proteome research.
[13] B. Shields,et al. Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes , 2011, Diabetes Care.
[14] C. Bellanné-Chantelot,et al. The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3 , 2008, Diabetes.
[15] Louise Royle,et al. Proposal for a standard system for drawing structural diagrams of N‐ and O‐linked carbohydrates and related compounds , 2009, Proteomics.
[16] K. Owen,et al. Diagnosis and management of maturity onset diabetes of the young (MODY) , 2011, BMJ : British Medical Journal.
[17] J. Skupień,et al. Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young , 2008, Diabetes Care.
[18] R Apweiler,et al. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.
[19] A. Hattersley,et al. The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria. , 2001, Diabetes.
[20] J. Skupień,et al. Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. , 2007, The review of diabetic studies : RDS.
[21] S. Ellard,et al. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity‐onset diabetes of the young , 2006, Human mutation.
[22] L. Groop,et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA , 2010, Journal of internal medicine.
[23] S. Ellard,et al. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young , 2008, Diabetologia.
[24] A. Brown,et al. Serum amino acids in patients with mutations in the hepatocyte nuclear factor‐1 alpha gene , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[25] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[26] M. McCarthy,et al. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes , 2011, Diabetologia.
[27] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[28] P. Boutin,et al. Anatomy of a Homeoprotein Revealed by the Analysis of Human MODY3 Mutations* , 1999, The Journal of Biological Chemistry.
[29] B. Shields,et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin‐treated patients , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[30] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[31] I. Rudan,et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. , 2010, Glycobiology.
[32] Wei Wang,et al. Genomics Meets Glycomics—The First GWAS Study of Human N-Glycome Identifies HNF1α as a Master Regulator of Plasma Protein Fucosylation , 2010, PLoS genetics.
[33] A. Hattersley,et al. Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.
[34] Richard D. Cummings,et al. The repertoire of glycan determinants in the human glycome. , 2009, Molecular bioSystems.
[35] M. McCarthy,et al. Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes , 2010, Diabetes Care.
[36] A. Hattersley,et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. , 2003, Diabetes.
[37] A. Hattersley,et al. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. , 2006, Human molecular genetics.
[38] M. McCarthy,et al. Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations , 2010, Diabetes Care.
[39] J. Copas,et al. Overestimation of the receiver operating characteristic curve for logistic regression , 2002 .